Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

19.4%

6 terminated/withdrawn out of 31 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

23%

7 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

7 recruiting6 with results6 terminated

Enrollment Performance

Analytics

Phase 1

13(44.8%)

Phase 2

9(31.0%)

Phase 3

7(24.1%)

29Total

Phase 1(13)

Phase 2(9)

Phase 3(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials

NCT06254495Phase 1Terminated

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Role: lead

NCT05983133Phase 1Terminated

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Role: lead

NCT06157892Phase 2Recruiting

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Role: lead

NCT04879329Phase 2Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Role: lead

NCT05208762Phase 1Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Role: lead

NCT05911295Phase 3Active Not Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Role: lead

NCT04404283Phase 3Active Not Recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Role: lead

NCT05132582Phase 3Active Not Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Role: lead

NCT04389632Phase 1Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Role: lead

NCT03485209Phase 2Active Not Recruiting

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Role: lead

NCT06131840Phase 1Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Role: lead

NCT05571839Phase 1Active Not Recruiting

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Role: lead

NCT03786081Phase 1Terminated

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Role: lead

NCT03975647Phase 3Active Not Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Role: lead

NCT04539938Phase 2Completed

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Role: lead

NCT06012435Phase 3Active Not Recruiting

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Role: lead

NCT05253651Phase 3Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Role: lead

NCT04609566Phase 2Completed

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Role: lead

NCT04227847Phase 1Recruiting

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Role: lead

NCT06003231Phase 2Active Not Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Role: lead